November 27 - 30, 2018
Loews Miami Beach Hotel
Miami Beach, Florida, USA
Abstract submission deadline: Friday, September 7
Advance registration deadline: Friday, October 12
ACCREDITATION STATEMENTThe American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
CREDIT DESIGNATION STATEMENTAACR has designated this live activity for a maximum of 20.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
CLAIMING (CME) CREDITPhysicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the CME Request for Credit Survey by Friday, January 11, 2019. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available on this website and via email. Your CME certificate will be sent to you via email after the completion of the activity.
STATEMENT OF EDUCATIONAL NEED, TARGET AUDIENCE, AND LEARNING OBJECTIVESThe field of immunotherapy is one of the most promising in cancer research. Utilizing the body’s immune system to fight cancer is often safer and better tolerated than traditional cancer treatments such as chemotherapy and radiation. Study and understanding of the immune system’s response to cancer has increased exponentially over the past several years, and this has given rise to many breakthrough cancer treatments. Types of immunotherapies include monoclonal antibodies (including checkpoint inhibitors), adoptive cell transfer (including CAR T cell therapy), therapeutic vaccines, cytokines, and oncolytic viruses.
Current promising treatments include monoclonal antibodies; radio- or chemolabeled monoclonal antibodies; bispecific monoclonal antibodies; checkpoint inhibitors such as PD-1, PD-L1, and CTLA-4 inhibitors, which have been approved for treatment of many cancers; cancer vaccines for treatment and prevention; cytokines such as interleukins and interferons; and immunomodulatory drugs that boost immune system function.
This conference will feature some of the world’s premier oncologists who will present their latest research on current immunotherapies. It will also help bridge the gap between the advances that are underway in the lab and their application to clinical practice. Particularly, this conference will feature talks from scientists working in cutting edge fields such as biomarkers and molecular targets, as well as different perspectives of metabolism, the microbiome, and whole systems biology, which will lead to a deeper understanding of the immune response to cancer.
Only through a thorough understanding of the basic immunologic science behind these new technologies and collaboration between basic scientists and oncologists can new treatments be developed. For physicians to best aid patients, they must have a solid and current understanding of the complexities of basic immunotherapy and new advances taking place in the lab that can eventually be applied to the clinic. Physicians will leave this conference with knowledge of novel advancements in immunotherapy in the lab and their potential for therapeutic applications.
After participating in this CME activity, physicians should be able to:
1. Identify and integrate novel strategies for analyzing tumors.2. Evaluate novel biomarkers or neoantigens and genomics to assess patients’ individual cancer and potential responses to treatment, and to personalize therapy.3. Explain the role of the gut microbiome and metabolism in tumor progression.4. Analyze the role of myeloid and immunomodulatory pathways in inflammation and in the tumor microenvironment.5. Integrate novel combination and targeted therapies for personalizing cancer immune responses.6. Identify novel checkpoints that can be exploited for therapy.
DISCLOSURE STATEMENTIt is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
ACKNOWLEDGMENT OF FINANCIAL OR OTHER SUPPORT
This activity is supported by Professional Educational grants and will be disclosed at the activity.
QUESTIONS ABOUT CME?Please contact the Office of CME at (215) 440-9300 or